EPIgenetics and in Vivo Resistance of Chronic Myeloid Leukemia Stem Cells to Tyrosine Kinase Inhibitors

This study is examining genetic and epigenetic (how genes are switched on or off) changes in the cancer stem cells of patients with newly diagnosed chronic myeloid leukemia (CML) to understand why some patients' leukemia cells become resistant to standard TKI (tyrosine kinase inhibitor) medications over time. **You may be eligible if...** - You are over 18 years old - You have been newly diagnosed with chronic myeloid leukemia in the chronic phase (early stage) - You have not yet received any treatment for CML at the time of your first blood sample - Your doctor plans to treat you with a TKI (such as imatinib, dasatinib, or nilotinib) as first-line therapy - You have health insurance coverage **You may NOT be eligible if...** - You have a medical reason that prevents you from taking TKI drugs - You are unlikely to be compliant with the treatment schedule - You have already been treated for CML previously Talk to your doctor to see if this trial is right for you.